Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113


CCR5 N-terminal region plays a critical role in HIV-1 inhibition by Toxoplasma gondii-derived cyclophilin-18.

Golding H, Khurana S, Yarovinsky F, King LR, Abdoulaeva G, Antonsson L, Owman C, Platt EJ, Kabat D, Andersen JF, Sher A.

J Biol Chem. 2005 Aug 19;280(33):29570-7. Epub 2005 Jun 23.


Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii.

Yarovinsky F, Andersen JF, King LR, Caspar P, Aliberti J, Golding H, Sher A.

J Biol Chem. 2004 Dec 17;279(51):53635-42. Epub 2004 Oct 6.


Inhibition of HIV-1 infection by a CCR5-binding cyclophilin from Toxoplasma gondii.

Golding H, Aliberti J, King LR, Manischewitz J, Andersen J, Valenzuela J, Landau NR, Sher A.

Blood. 2003 Nov 1;102(9):3280-6. Epub 2003 Jul 10.


Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein.

Blanpain C, Doranz BJ, Vakili J, Rucker J, Govaerts C, Baik SS, Lorthioir O, Migeotte I, Libert F, Baleux F, Vassart G, Doms RW, Parmentier M.

J Biol Chem. 1999 Dec 3;274(49):34719-27.


CCR5 N-terminus peptides enhance X4 HIV-1 infection by CXCR4 up-regulation.

Dettin M, Zanchetta M, Pasquato A, Borrello M, Piatier-Tonneau D, Di Bello C, De Rossi A.

Biochem Biophys Res Commun. 2003 Aug 1;307(3):640-6.


V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.

PLoS Pathog. 2007 Aug 24;3(8):e117.


Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.

Pastore C, Picchio GR, Galimi F, Fish R, Hartley O, Offord RE, Mosier DE.

Antimicrob Agents Chemother. 2003 Feb;47(2):509-17.


Human alpha1-acid glycoprotein binds to CCR5 expressed on the plasma membrane of human primary macrophages.

Atemezem A, Mbemba E, Vassy R, Slimani H, Saffar L, Gattegno L.

Biochem J. 2001 May 15;356(Pt 1):121-8.


A short amino acid sequence containing tyrosine in the N-terminal region of G protein-coupled receptors is critical for their potential use as co-receptors for human and simian immunodeficiency viruses.

Shimizu N, Tanaka A, Oue A, Mori T, Apichartpiyakul C, Hoshino H.

J Gen Virol. 2008 Dec;89(Pt 12):3126-36. doi: 10.1099/vir.0.2008/002188-0.


Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II.

Luo Z, Fan X, Zhou N, Hiraoka M, Luo J, Kaji H, Huang Z.

Biochemistry. 2000 Nov 7;39(44):13545-50.


Characterization of the role of the N-loop of MIP-1 beta in CCR5 binding.

Bondue A, Jao SC, Blanpain C, Parmentier M, LiWang PJ.

Biochemistry. 2002 Nov 19;41(46):13548-55.


A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs.

de Parseval A, Bobardt MD, Chatterji A, Chatterji U, Elder JH, David G, Zolla-Pazner S, Farzan M, Lee TH, Gallay PA.

J Biol Chem. 2005 Nov 25;280(47):39493-504. Epub 2005 Sep 12.


Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.

Imai M, Baranyi L, Okada N, Okada H.

Biochem Biophys Res Commun. 2007 Feb 23;353(4):851-6. Epub 2006 Dec 21.


Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.

Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF.

AIDS. 2008 Jul 31;22(12):1425-31. doi: 10.1097/QAD.0b013e32830184ba.


TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.

Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M, Iizawa Y.

Antimicrob Agents Chemother. 2005 Nov;49(11):4584-91.


Comparison of ligand-based and receptor-based virtual screening of HIV entry inhibitors for the CXCR4 and CCR5 receptors using 3D ligand shape matching and ligand-receptor docking.

Pérez-Nueno VI, Ritchie DW, Rabal O, Pascual R, Borrell JI, Teixidó J.

J Chem Inf Model. 2008 Mar;48(3):509-33. doi: 10.1021/ci700415g. Epub 2008 Feb 26.


Supplemental Content

Support Center